<p><h1>Zoster Vaccine Live Market: A Comprehensive Report of its Market Share & Growth Trends 2024 - 2031</h1></p><p><strong>Zoster Vaccine Live Market Analysis and Latest Trends</strong></p>
<p><p>Zoster Vaccine Live is a vaccine used to prevent shingles in adults aged 50 years and older, as well as to reduce the risk of complications associated with the disease. The vaccine works by stimulating the immune system to produce antibodies against the varicella-zoster virus.</p><p>The Zoster Vaccine Live Market is expected to grow at a CAGR of 7.1% during the forecast period. The market growth can be attributed to the increasing prevalence of shingles, growing awareness about vaccination, and the expanding elderly population worldwide. Additionally, advancements in healthcare infrastructure and government initiatives to promote vaccination programs are further driving the market growth.</p><p>The latest trends in the Zoster Vaccine Live Market include the development of new and innovative vaccines with improved efficacy and safety profiles, strategic collaborations between healthcare organizations and vaccine manufacturers, and the increasing adoption of vaccination campaigns in developing countries. Moreover, the rising focus on preventive healthcare and the growing demand for advanced healthcare solutions are expected to propel the market growth in the coming years.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1669353">https://www.reliableresearchreports.com/enquiry/request-sample/1669353</a></p>
<p>&nbsp;</p>
<p><strong>Zoster Vaccine Live Major Market Players</strong></p>
<p><p>The Zoster Vaccine Live market is dominated by major players such as Merck and GSK. Merck's Zostavax and GSK's Shingrix are the two main vaccines available in the market for the prevention of shingles. </p><p>Merck & Co. is a leading global healthcare company known for its extensive portfolio of vaccines, pharmaceuticals, and biologics. The company has a strong presence in the Zoster Vaccine Live market with its highly effective vaccine, Zostavax. Merck has shown steady market growth over the years due to the increasing prevalence of shingles and the growing awareness about the importance of vaccination. The company is focused on expanding its market presence by developing new and innovative vaccines to meet the evolving needs of patients.</p><p>GlaxoSmithKline (GSK) is another key player in the Zoster Vaccine Live market with its vaccine Shingrix. GSK has a robust pipeline of vaccines and a strong global distribution network, which have helped the company gain a significant market share in the Zoster Vaccine Live market. Shingrix has been widely praised for its high efficacy and long-lasting protection against shingles, which has contributed to its rapid market growth.</p><p>In terms of sales revenue, Merck reported a revenue of $7.3 billion from its vaccines segment in 2020, with Zostavax being a major contributor to this figure. GSK, on the other hand, reported a revenue of $1.7 billion from its vaccines segment in 2020, with Shingrix playing a key role in driving this revenue.</p><p>Both Merck and GSK are expected to witness continued growth in the Zoster Vaccine Live market in the coming years, driven by the increasing demand for shingles vaccines and the expanding geriatric population worldwide. The market size for Zoster Vaccine Live is expected to grow significantly, with a CAGR of 5.8% from 2021 to 2028, according to industry reports.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Zoster Vaccine Live Manufacturers?</strong></p>
<p><p>The Zoster Vaccine Live market is experiencing steady growth due to the rising geriatric population worldwide and increasing awareness about the importance of vaccination for preventing shingles. The market is expected to witness significant expansion in the coming years as more people seek protection against this painful condition. Factors such as technological advancements in vaccine production and government initiatives to promote immunization programs are also contributing to the market's growth. Overall, the Zoster Vaccine Live market is poised for robust growth in the future, with key players focusing on expanding their product offerings and reaching a larger consumer base.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1669353">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1669353</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Zoster Vaccine Live Market Analysis by types is segmented into:</strong></p>
<p><ul><li>Monovalent Vaccine</li><li>Combination Vaccine</li></ul></p>
<p><p>Zoster Vaccine Live market offers two main types of vaccines: Monovalent Vaccine and Combination Vaccine. Monovalent Vaccine contains only one strain of the live attenuated virus, providing protection against a specific virus strain. On the other hand, Combination Vaccine combines multiple strains of the virus in a single vaccine, offering broader protection against various strains. Both types aim to prevent herpes zoster, commonly known as shingles, by boosting the immune system's response to the varicella-zoster virus.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1669353">https://www.reliableresearchreports.com/purchase/1669353</a></p>
<p>&nbsp;</p>
<p><strong>The Zoster Vaccine Live Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Kids Injection</li><li>Adults Injection</li></ul></p>
<p><p>Zoster Vaccine Live is a commonly used vaccination for children and adults to prevent shingles, a painful skin rash caused by the varicella-zoster virus. The vaccine is administered through an injection and is recommended for both children and adults to protect against developing shingles later in life. Children and adults alike benefit from receiving the Zoster Vaccine Live to reduce the risk of experiencing the painful symptoms associated with shingles.</p></p>
<p><a href="https://www.reliableresearchreports.com/zoster-vaccine-live-r1669353">&nbsp;https://www.reliableresearchreports.com/zoster-vaccine-live-r1669353</a></p>
<p><strong>In terms of Region, the Zoster Vaccine Live Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The Zoster Vaccine Live market is expected to witness significant growth across various regions such as North America (NA), Asia Pacific (APAC), Europe, United States (USA), and China. Among these regions, North America is anticipated to dominate the market with a market share of 45%, followed by Europe with 30%, Asia Pacific with 15%, United States with 7%, and China with 3%. This growth can be attributed to increasing awareness about vaccine-preventable diseases and government initiatives towards immunization programs.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1669353">https://www.reliableresearchreports.com/purchase/1669353</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1669353">https://www.reliableresearchreports.com/enquiry/request-sample/1669353</a></p>
<p><strong></strong></p>
<p><p><a href="https://view.publitas.com/reportprime-1/blood-alcohol-breathing-monitor-market-outlook-industry-overview-and-forecast-2024-to-2031/">Blood Alcohol Breathing Monitor Market</a></p><p><a href="https://view.publitas.com/reportprime-1/hydrogen-breathing-monitor-market-trends-and-market-analysis-forecasted-for-period-2024-2031/">Hydrogen Breathing Monitor Market</a></p><p><a href="https://view.publitas.com/reportprime-1/pediatric-ecg-electrode-market-trends-forecast-and-competitive-analysis-to-2031/">Pediatric ECG Electrode Market</a></p></p>